NCT02893189View on ClinicalTrials.gov

CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 27, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2022

Conditions
CD19+ Malignancies: Relapse Post-allogeneic Transplant
Interventions
GENETIC

Infusion of modified CAR19 T-cells (4G7-CARD T-cells)

The original stem cells donor (or if not available the patient) will undergo unstimulated leucapheresis for generation of the Advanced Therapy Interventional Medicinal Product (ATIMP) 4G7-CARD T-cells. Escalating doses of the ATIMP will then be infused to the patient depending on outcome and any experienced side effects.

Trial Locations (1)

Unknown

University College London Hospital, London

All Listed Sponsors
lead

University College, London

OTHER

NCT02893189 - CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation | Biotech Hunter | Biotech Hunter